Main Category: Arthritis / Rheumatology
Also Included In: Bones / Orthopedics; Clinical Trials / Drug Trials; Pharma Industry / Biotech Industry
Article Date: 01 Jun 2011 – 0:00 PDT
email to a friend printer friendly opinions
<!– rate article
Patient / Public:
Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE)(“Ampio”) announced that it received ethics board approval for a Phase 1B clinical trial in Australia of its biologic anti-inflammatory agent, Ampion™. Patients are now being recruited for first dosing in the three arm, placebo controlled, 60 patient trial designed to demonstrate efficacy in the treatment of osteoarthritis of the knee as well as to confirm patient safety and tolerance.
The present “standard of care” treatment for this condition is the injection of a short acting local anesthetic agent combined with a long acting steroid into and around the joint. In the Ampion trial the mitigation of pain and loss of function caused by osteoarthritis will be assessed at intervals from the time of injection. Patients will be evaluated for 72 hours and various parameters will be followed to demonstrate that Ampion™ is well tolerated and provides pain relief through decreased inflammation as well as demonstrated improvement in the range of motion of the knee.
Dr. David Bar-Or, MD, Ampio’s Chief Scientific Officer, noted, “We discovered this molecule in patients with severe head injury who experienced decreased immune/inflammatory function. The molecule is produced in the body from our own serum albumin and is the most abundant protein in human plasma. We realized from our studies in human tissue that this molecule is an integral part of the innate control of inflammation. We know of many molecules made by our body that increase inflammation but of very few that decrease it. We are hopeful that Ampion™, with few or no side effects, will provide real relief for patients suffering from chronic inflammatory conditions,” stated Dr. Bar-Or.
Ampio CEO Don Wingerter noted, “Since Ampion™ is a biologic product made by our bodies, we believe there is the probability of markedly greater safety than steroids or other anti-inflammatory drugs. We anticipate this clinical trial will demonstrate sufficient proof of safety and efficacy to allow longer term studies in which relief may be obtained without prolonged use of steroids, especially when knee replacement is not an option. We are hopeful this drug will provide clinical utility and safety greater than products now selling in the multi-billion dollar market for anti-inflammatories.”
Vaughan Clift, MD, Ampio’s Chief Regulatory Officer added, “We are very grateful to our Australian Principal Investigators, Dr. Peter Lewis and Dr. Andrew Comley, who helped in the design of the trial and approval process and whose leadership has resulted in encouraging support from local General Practitioners who are also identifying and referring patients into this AIK (Ampion in knee) trial. We expect the trial results will form the basis for submissions to various regulatory agencies to conduct Phase II/III studies of the active component in numerous inflammatory conditions. We believe the nature of the compound and its human origin should facilitate a faster regulatory approval path in most countries compared to the traditional new drug therapies.”
More about Zertane™ Phase III Clinical trial Results
On another note, CEO Wingerter added: “Our May 23, 2011 press release relating to the results of our Phase III study for our male sexual dysfunction drug, Zertane™, used for the treatment of premature ejaculation, generated significant inquiries that led us to provide additional information on our website about the medical condition and the trial results in a QA format. Ampio expects to shortly present a web-based conference of the trial results that will include comparisons to published data on the only other PE drug currently marketed in Europe as well as our commercial strategic plan for this product.”
Source: Ampio Pharmaceuticals, Inc
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.
Follow us on Twitter
Arthritis / Rheumatology headlines
email to a friend
printer friendly version
personalize your news
back to top
Please note that we publish your name, but we do not publish your email address. It is only used to let
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Terms and Conditions
MediLexicon International Ltd
MediLexicon International Ltd © 2004-2011 All rights reserved.